Publications by authors named "Lerato Mohapi"

Claim this Profile
V
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study.
Jean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, Cissy Kityo, Michael D Hughes, Lerato Mohapi

Lancet HIV· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites.
Cissy Kityo, Caitlyn McCarthy, Serena P Koenig, Michael D Hughes, Carole L Wallis, Lerato Mohapi

Open Forum Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis.
Sonya Krishnan, Xingye Wu, Soyeon Kim, Katie McIntire, Linda Naini, Lerato Mohapi

Clin Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial.
Mariana Araújo-Pereira, Sonya Krishnan, Padmini Salgame, Yukari C Manabe, Mina C Hosseinipour, Lerato Mohapi

EClinicalMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household.
Soyeon Kim, Anneke C Hesseling, Xingye Wu, Michael D Hughes, N Sarita Shah, Lerato Mohapi

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, Andrew Vernon, Payam Nahid, Lerato Mohapi

Clin Infect Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Anthony T Podany, Michelle Pham, Erin Sizemore, Neil Martinson, Wadzanai Samaneka, Lerato Mohapi

Clin Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Michelle M Pham, Anthony T Podany, Noluthando Mwelase, Khuanchai Supparatpinyo, Lerato Mohapi

Antimicrob Agents Chemother· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Anchalee Avihingsanon, Michael D Hughes, Robert Salata, Catherine Godfrey, Caitlyn McCarthy, Lerato Mohapi

J Int AIDS Soc· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
Lerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, Khuanchai Supparatpinyo, Winai Ratanasuwan

AIDS· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.
Sonya Krishnan, Artur T L Queiroz, Amita Gupta, Nikhil Gupte, Gregory P Bisson, Lerato Mohapi

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants.
Rebecca T Henry, Awachana Jiamsakul, Matthew Law, Marcelo Losso, Adeeba Kamarulzaman, Lerato Mohapi

J Acquir Immune Defic Syndr· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
David W Haas, Anthony T Podany, Yajing Bao, Susan Swindells, Richard E Chaisson, Lerato Mohapi

Pharmacogenet Genomics· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.
Edgar T Overton, Amy Kantor, Kathleen V Fitch, Paul Muntner, Khuanchai Supparatpinyo, Lerato Mohapi

J Infect Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study.
Nishi Suryavanshi, Matthew Murrill, Amita Gupta, Michael Hughes, Anneke Hesseling, Lerato Mohapi

Clin Infect Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.
Amita Gupta, Susan Swindells, Soyeon Kim, Michael D Hughes, Linda Naini, Lerato Mohapi

Clin Infect Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV research in South Africa: Advancing life.
G Gray, Tanya Doherty, Lerato Mohapi, Jenny Coetzee, Kathryn L Hopkins

S Afr Med J· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Beatriz Grinsztejn, Michael D Hughes, Justin Ritz, Robert Salata, Peter Mugyenyi, Lerato Mohapi

Lancet HIV· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
Conor D Tweed, Angela M Crook, Rodney Dawson, Andreas H Diacon, Timothy D McHugh, Lerato Mohapi

BMC Pulm Med· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV.
Paula Munderi, Edwin Were, Anchalee Avihingsanon, Pascale A M Mbida, Lerato Mohapi

South Afr J HIV Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Susan Swindells, Ritesh Ramchandani, Amita Gupta, Constance A Benson, Jorge Leon-Cruz, Lerato Mohapi

N Engl J Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Conor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, Rodney Dawson, Andreas H Diacon, Lerato Mohapi

BMC Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy.
Gwamaka E Mwasakifwa, Cecilia Moore, Dianne Carey, Janaki Amin, Paul Penteado, Lerato Mohapi

AIDS· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Mark A Boyd, Janaki Amin, Patrick W G Mallon, Nagalingeswaran Kumarasamy, Johan Lombaard, Lerato Mohapi

Lancet HIV· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Mina C Hosseinipour, Gregory P Bisson, Sachiko Miyahara, Xin Sun, Agnes Moses, Lerato Mohapi

Lancet· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis